Korean Circ J.  1981 Jun;11(1):113-119. 10.4070/kcj.1981.11.1.113.

Clinical Effect of Procetofene(Lipanthyl(R)) on the Serum Lipids in the Hyperlipidemic Patients

• Choi YS
• Park JS
• Seo J
• Lee YW

• KMID: 1668349
• DOI: http://doi.org/10.4070/kcj.1981.11.1.113

Abstract

We observed the levels of serum cholesterol, triglyceride and HDL-cholesterol in 28-hyperlipidemic patients after treatment with procetofene(Lipanthyl(R)), a new hypolipidemic agent. The results were as follows. 1. The hyperlipidemic patients were 7 cases of pure hypercholesterolemia, 12 cases of mixed hyperlipidemia and 9 cases of pure hypertriglyceridemia. 2. All the patients were treated with daily dose of 200 to 400mg, usually 300mg, and duration of more than 12 weeks. 3. The serum cholesterol decreased significantly at the rate of 29% in pure hypercholes terolemia and 29% in mixed hyperlipidemia after treatment for 12 weeks. 4. The serum triglyceride decreased significantly at the rate of 58% in mixed hyperlipidemia and 42% in pure hypertriglyceridemia after treatment for 12 weeks. 5. The serum HDL-cholesterol increased at the rate of 10% in pure hypercholesterolemia, 14% in mixed hyperlipidemia and 26% in pure hypertriglyceridemia after treatment for 12 weeks, but the increase rate was statistically significant only in pure hypertriglyceridemia. 6. Transient epigastric discomfort was complained by 2 patients, but subsided spontaneously with continuous treatment. 7. In view of these results, procetofene appears to be an effective and well tolerated agent for the treatment of all the types of hyperlipidemia.

MeSH Terms

Cholesterol
Fenofibrate
Humans
Hypercholesterolemia
Hyperlipidemias
Hypertriglyceridemia
Triglycerides
Cholesterol
Fenofibrate